AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29096678
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered alteplase
Trial: 26416029
Drug: Parent-Child Interaction
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Child Interaction Therapy (EBT)
Trial: 23415985
Drug: Medication combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication combined with chewing gum
Trial: 21978087
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy in addition to routine nursing care
Trial: 19303969
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin treatment (3 to 4 injections of insulin daily)
Trial: 19303969
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin treatment plus an additional day per week of 3 intravenous pulses over an 8‐hour period
Trial: 7923312
Drug: Ibuprofen lysine
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen lysine 200 mg (IBL 200)
Trial: 7923312
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 500 mg (ASA 500)
Trial: 2971512
Drug: 1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 percent clindamycin phosphate gel
Trial: 2971512
Drug: 1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 percent clindamycin phosphate solution
Trial: 2971512
Drug: Placebo (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gel vehicle)
Trial: 23294132
Drug: Continuous Infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Infusion
Trial: 22708640
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg daily)
Trial: 21536983
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (50 to 100 mg daily)
Trial: 19561368
Drug: Virtual-reality-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual-reality-based exercise bike therapy
Trial: 19561368
Drug: Standard rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rehabilitation therapy without virtual-reality equipment
Trial: 11590875
Drug: 5.2 g
RxNorm normalized name: Veltassa 25.2 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.2 g n‐3 PUFA daily for 12 weeks
Trial: 9125088
Drug: Chemical/Biological Combat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical/Biological Combat Suit (CBCS)
Trial: 2979237
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized testosterone (200 mg t.d.s.)
Trial: 27049056
Drug: Test spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test spironolactone tablet formulation (100 mg) under fasting condition
Trial: 27049056
Drug: Test spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test spironolactone tablet formulation (100 mg) under fed condition
Trial: 27049056
Drug: Reference spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference spironolactone tablet formulation (100 mg) under fasting condition
Trial: 27049056
Drug: Reference spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference spironolactone tablet formulation (100 mg) under fed condition
Trial: 23857878
Drug: Various drugs
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various drugs (90 drugs assessed)
Trial: 23857878
Drug: Trimipramine (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine (tricyclic antidepressant)
Trial: 6378303
Drug: Clomipramine (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (tricyclic antidepressant)
Trial: 23857878
Drug: Chlorpromazine (antipsychotic)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (antipsychotic)
Trial: 23857878
Drug: Sotalol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (beta blocker)
Trial: 23857878
Drug: Itraconazole (antifungal)
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole (antifungal)
Trial: 23857878
Drug: Phenylpropanolamine (decongestant/anorectic)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (decongestant/anorectic)
Trial: 1525787
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg once daily
Trial: 8040678
Drug: Epirubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin and dexrazoxane (600/120 mg/m2, 900/120 mg/m2, 900/135 mg/m2, 900/150 mg/m2, 1,200/135 mg/m2)
Trial: 2493868
Drug: Counselling by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling by health visitors (8 weekly visits)
Trial: 9890791
Drug: Dipropylacetate (Depakine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipropylacetate (Depakine, 20 mg/kg)
Trial: 9890791
Drug: Phenobarbital (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (5 mg/kg)
Trial: 9890791
Drug: Primidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primidone (25 mg/kg)
Trial: 28193663
Drug: Patient-targeted education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-targeted education about the etiology of URTIs, the role of antibiotics, and consequences of inappropriate antibiotic use.
Trial: 9175371
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic combined with piroxicam eye drops
Trial: 9175371
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic eye drops alone
Trial: 1283661
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (EACA) 5 g administered after induction of anesthesia and 2 g/h during surgery
Trial: 1283661
Drug: Aprotinin (APROT)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin (APROT) 2.10(6) UIK administered after induction of anesthesia and 5.10(5) UIK/h during surgery
Trial: 30700474
Drug: Perioperative CapeOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative CapeOX chemotherapy (up to four cycles every 3 weeks) plus radical surgery plus up to four cycles of postoperative chemotherapy
Trial: 30700474
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (up to eight cycles after radical surgery)
Trial: 27062400
Drug: Family Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Based Treatment (FBT)
Trial: 27062400
Drug: Systemic Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Family Therapy (SyFT)
Trial: 22955513
Drug: Moderate fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate fat ingestion (MF) - 0.7 g of fat/kg body weight
Trial: 22955513
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat ingestion (LF) - 0.4 g of fat/kg body weight
Trial: 17914085
Drug: Subcutaneous granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous granisetron (3 mg)
Trial: 17914085
Drug: Intravenous granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous granisetron (3 mg)
Trial: 16208801
Drug: Oscillating/pulsating power
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating/pulsating power toothbrush (Oral‐B ProfessionalCare 7000; PC 7000)
Trial: 3155240
Drug: Immunoglobulin treatment
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin treatment
Trial: 10419244
Drug: High-dose steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroids treatment
Trial: 30223911
Drug: ADT+brexpiprazole 1-3
RxNorm normalized name: brexpiprazole 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT+brexpiprazole 1-3 mg/day
Trial: 26458986
Drug: Movi-Kids intervention
RxNorm normalized name: Mederma for Kids
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Movi-Kids intervention (three hour-long sessions of recreational non-competitive physical activity after school, weekly; educational materials for parents and teachers; playground modifications)
Trial: 21819824
Drug: Standard monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monitoring by the Motor Vehicle Administration (Control)
Trial: 11583878
Drug: Constant medical
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant medical therapy
Trial: 7534847
Drug: Preventive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive therapy with pantripin and contrykal
Trial: 3309812
Drug: Pefloxacin infusion
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin infusion for one hour
Trial: 31754703
Drug: Darunavir/ritonavir (800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (800/100 mg) + raltegravir (400 mg)
Trial: 31754703
Drug: Darunavir/ritonavir (800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (800/100 mg) + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily)
Trial: 19861543
Drug: 3.0-g bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0-g bovine lactoferrin (bLF) daily for 12 months
Trial: 19861543
Drug: 1.5-g bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5-g bovine lactoferrin (bLF) daily for 12 months
Trial: 16518959
Drug: Enfuvirtide (ENF)
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (ENF) in combination with lopinavir/ritonavir, efavirenz, lamivudine, and tenofovir
Trial: 16518959
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no enfuvirtide) with the same four-drug regimen
Trial: 9407455
Drug: AST-120 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (6 g/day) concurrent with low protein diet (LPD)
Trial: 8508355
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with vincristine (VCR)
Trial: 8508355
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy without vincristine (VCR)
Trial: 8508355
Drug: 12 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 courses of maintenance‐intensification therapy
Trial: 8508355
Drug: 4 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 courses of maintenance‐intensification therapy
Trial: 3479420
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg orally twice daily for 14 days
Trial: 3479420
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg orally twice daily for 14 days
Trial: 25616042
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) at doses of 200-400 mg/kg
Trial: 25616042
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) at doses of 600-800 mg/kg
Trial: 17295082
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam irradiation (EBI) plus antiplatelet therapy
Trial: 15170163
Drug: Sequential skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential skin biopsies
Trial: 11585352
Drug: Continuous ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ibandronate 2.5 mg daily (n = 81)
Trial: 11585352
Drug: Intermittent ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent ibandronate 20 mg every other day for the first 24 days (n = 78)
Trial: 11585352
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (continuous and intermittent)
Trial: 8555958
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray (NNS)
Trial: 2496789
Drug: Nimodipine 60
RxNorm normalized name: nimodipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 60 mg orally every four hours for 21 days
Trial: 723760
Drug: Clofibate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate (2 X 1 g)
Trial: 723760
Drug: Bezafibrate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (3 X 150 mg)
Trial: 29725824
Drug: Intervention spread
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention spread with 2.0 g/day plant sterols and 1.0 g/day EPA+DHA from fish oil
Trial: 25127179
Drug: Face-to-face ACT
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face ACT treatment
Trial: 22376210
Drug: Test gel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test gel (anesthetic gel)
Trial: 9706859
Drug: Test gel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test gel
Trial: 17495015
Drug: Adapted-dose azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adapted-dose azathioprine therapy (adjusted to maintain 6-TGN concentrations between 250 and 400 pmol/8 x 10(8) erythrocytes)
Trial: 17495015
Drug: Standard-dose azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose azathioprine therapy (2.5 mg/kg/day)
Trial: 17495015
Drug: Adapted-dose azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adapted-dose azathioprine therapy
Trial: 17495015
Drug: Standard-dose azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose azathioprine therapy
Trial: 8313125
Drug: Peripheral IVN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral IVN system with fine-bore silicone catheter and lipid-based nutrient solutions
Trial: 2478330
Drug: Antithrombin III/low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III/low-dose heparin (ATIII/LDH) regimen (3000 units loading dose followed by 2000 units daily and 5000 units of LDH twice daily)
Trial: 2478330
Drug: Low-molecular-weight dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight dextran (LMWD) (10 ml/kg x 12 hours loading dose followed by 7 ml/kg x 24 hours maintenance dose)
Trial: 786311
Drug: WA 335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WA 335 (3 X 1 mg/die)
Trial: 786311
Drug: Amitriptyline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (3 X 50 mg/die)
Trial: 28235726
Drug: CCRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT plus AC (adjuvant cisplatin 80 mg/m2 and fluorouracil 800 mg/m2/d for 120 h every 4 weeks for three cycles)
Trial: 22012289
Drug: II and
RxNorm normalized name: coagulation factor IX, II, VII and X in combination
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: II and IH nerve block with 10 mL of 0.75% ropivacaine and surgical wound infiltration with 10 mL of 0.75% ropivacaine
Trial: 22012289
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 15 mg hyperbaric 0.5% bupivacaine (Control Group)
Trial: 17403400
Drug: laxative (magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: laxative (magnesium oxide + disodium phosphate)
Trial: 15576019
Drug: 1.5 x
RxNorm normalized name: lisocabtagene maraleucel 1.5 x 10exp6 to 70 x 10exp6 cell/mL INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 x 10(6) IU of albumin-free recombinant streptokinase (rSK) in a one-hour intravenous infusion
Trial: 9609895
Drug: Perflenapent emulsion
RxNorm normalized name: perflenapent
DrugBank: Perflenapent (DB11625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perflenapent emulsion (0.05 mL/kg)
Trial: 31123001
Drug: Individualised antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised antiplatelet therapy based on pharmacogenetic information and clinical features (pharmacogenetic group)
Trial: 24618231
Drug: Concentrated ambient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ambient coarse particles (CAP; 76.2 ± 51.5 μg/m(3))
Trial: 19093773
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor cell-derived vaccines
Trial: 19093773
Drug: Allogeneic tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic tumor cell-derived vaccines
Trial: 18192950
Drug: Vasoactive agents
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive agents (inotropes and pressor agents)
Trial: 15167885
Drug: Early Total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Total Parenteral Nutrition (ETPN)
Trial: 15167885
Drug: Late Total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late Total Parenteral Nutrition (LTPN)
Trial: 11669169
Drug: Cyclosporine (CSA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CSA) 3 mg/kg/day
Trial: 11669169
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) 2,000 mg/day
Trial: 2847578
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium aerosol (2 inhalations; 2 mg/inhalation)
Trial: 31257987
Drug: Separate imputation
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate imputation by treatment group
Trial: 28213388
Drug: Dopamine donor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine donor pretreatment (4 µg/kg per minute continuous infusion)
Trial: 28213388
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dopamine infusion)
Trial: 28213388
Drug: Dopamine donor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine donor pretreatment with infusion time of 7.1 hours
Trial: 24613349
Drug: Atacicept 150
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept 150 mg
Trial: 23391369
Drug: AZD9668 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9668 (150 mg single dose, 70 mg twice daily multiple doses)
Trial: 19117833
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D and calcium supplementation (100,000 IU bimonthly and 1 g/day calcium)
Trial: 17674917
Drug: Combined 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) with silicone oil
Trial: 17674917
Drug: Silicone oil
RxNorm normalized name: SILICONE OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone oil without adjunctive medication (control group)